Tab-in-tab formulation of ramipril and nifedipine for effective anti-hypertensive activity

Pravin K. Shende , Vedraj V. Vellody , R.S. Gaud
{"title":"Tab-in-tab formulation of ramipril and nifedipine for effective anti-hypertensive activity","authors":"Pravin K. Shende ,&nbsp;Vedraj V. Vellody ,&nbsp;R.S. Gaud","doi":"10.1016/j.jopr.2013.06.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The aims of this work were to enhance the solubility of nifedipine in acidic medium; to formulate and characterize tab-in-tab dosage form for immediate release of nifedipine and controlled release of ramipril and to avoid the mutual interactions of drugs. This combination appreciably intended to reduce the incidence of peripheral edema and reflex tachycardia.</p></div><div><h3>Methods</h3><p>Ramipril was firstly wet granulated with a HPMC polymer to form stable granules and then was directly compressed to form a core tablet. Enteric coating was given with a water insoluble polymer to withstand the acidic pH of stomach. Initially, nifedipine microcapsules were prepared, granulated with excipients and then compressed, keeping the inner tablet in between the granules.</p></div><div><h3>Results and discussion</h3><p>This novel tab-in-tab dosage form allowed the nifedipine to release for stomach-specific absorption and ramipril to the intestine-specific absorption. Distinctive release profiles were obtained for immediate- and controlled-release tab-in-tab formulations, giving better bioavailability with no metabolic side-effects.</p></div><div><h3>Conclusion</h3><p>Tab-in-tab drug delivery system used to formulate combination drugs with different pharmacokinetic profiles provide reduction in dosage, dosing frequency, reduction in side effects, additive effects and single pill convenience.</p></div>","PeriodicalId":16787,"journal":{"name":"Journal of Pharmacy Research","volume":"6 6","pages":"Pages 656-662"},"PeriodicalIF":0.0000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jopr.2013.06.008","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0974694313002430","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Background

The aims of this work were to enhance the solubility of nifedipine in acidic medium; to formulate and characterize tab-in-tab dosage form for immediate release of nifedipine and controlled release of ramipril and to avoid the mutual interactions of drugs. This combination appreciably intended to reduce the incidence of peripheral edema and reflex tachycardia.

Methods

Ramipril was firstly wet granulated with a HPMC polymer to form stable granules and then was directly compressed to form a core tablet. Enteric coating was given with a water insoluble polymer to withstand the acidic pH of stomach. Initially, nifedipine microcapsules were prepared, granulated with excipients and then compressed, keeping the inner tablet in between the granules.

Results and discussion

This novel tab-in-tab dosage form allowed the nifedipine to release for stomach-specific absorption and ramipril to the intestine-specific absorption. Distinctive release profiles were obtained for immediate- and controlled-release tab-in-tab formulations, giving better bioavailability with no metabolic side-effects.

Conclusion

Tab-in-tab drug delivery system used to formulate combination drugs with different pharmacokinetic profiles provide reduction in dosage, dosing frequency, reduction in side effects, additive effects and single pill convenience.

雷米普利与硝苯地平片内联合处方有效降压
背景:提高硝苯地平在酸性介质中的溶解度;制定硝苯地平即刻释放和雷米普利控释的片内剂型,并对其进行表征,避免药物相互作用。这种组合明显旨在减少周围水肿和反射性心动过速的发生率。方法先用HPMC聚合物湿法制粒,使雷米普利形成稳定的颗粒,然后直接压缩制成芯片。肠包衣用不溶于水的聚合物来抵抗胃的酸性pH。首先制备硝苯地平微胶囊,用辅料制成颗粒,然后压缩,使内片保持在颗粒之间。结果与讨论这种新型片剂使硝苯地平释放为胃特异性吸收,雷米普利释放为肠特异性吸收。不同的释放曲线获得即时和控释片剂制剂,提供更好的生物利用度,没有代谢副作用。结论采用片内给药系统制备不同药动学特征的联合用药,可减少给药剂量、给药频次、减少毒副作用和加性效应,且单粒方便。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信